ACUSLABS
Financiado
A new tool in drug development mapping of compound protein interaction using fo...
A new tool in drug development mapping of compound protein interaction using forward genetics
Development of new medicines such as chemotherapeutic drugs requires a detailed understanding of their biological mechanism of action. What are the desired and undesired interactions with biological molecules? It is our goal to fo...
Development of new medicines such as chemotherapeutic drugs requires a detailed understanding of their biological mechanism of action. What are the desired and undesired interactions with biological molecules? It is our goal to found a start-up company that will provide a solution to this challenge. Using novel and ground-breaking approaches we can identify target structures and interaction partners of small bioactive molecules at an unmatched and unprecedented resolution. ERC PoC funding will be essential to support our activities to identify optimal strategies and initial customers for our service.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2017-06-20
Fecha Fin: 2018-12-31
Fecha Fin: 2018-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-PoC:
ERC-Proof of Concept
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
379.44K€ |
Participante